Although MAPT haplotypes tested to date in the literature clearly have smaller effect sizes than that of APOE genotypes for AD risk, it is nonetheless worthwhile to pursue this MAPT haplotype–stratified analysis not only because of its potential to identify novel loci but also because of the plethora of data implicating tau in AD in functional studies.20 The gene discussed is APOE; the disease is Alzheimer disease.